CA2441007A1 - Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids - Google Patents

Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids Download PDF

Info

Publication number
CA2441007A1
CA2441007A1 CA002441007A CA2441007A CA2441007A1 CA 2441007 A1 CA2441007 A1 CA 2441007A1 CA 002441007 A CA002441007 A CA 002441007A CA 2441007 A CA2441007 A CA 2441007A CA 2441007 A1 CA2441007 A1 CA 2441007A1
Authority
CA
Canada
Prior art keywords
inflammatory disorders
gastrointestinal tract
treating inflammatory
topical active
active corticosteroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002441007A
Other languages
French (fr)
Other versions
CA2441007C (en
Inventor
B. George Mcdonald
Nicholas Stergiopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soligenix Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2441007A1 publication Critical patent/CA2441007A1/en
Application granted granted Critical
Publication of CA2441007C publication Critical patent/CA2441007C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Abstract

A method of administration of inflammatory disorders of the intestinal tract, including inflammatory bowel disease, by oral administration of a composition including at least two dosage forms containing a topically active corticosteroid, such as beclomethasone (Figure 2).
CA002441007A 2001-03-15 2002-03-15 Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids Expired - Lifetime CA2441007C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27601301P 2001-03-15 2001-03-15
US60/276,013 2001-03-15
PCT/US2002/007676 WO2002074316A1 (en) 2001-03-15 2002-03-15 Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids

Publications (2)

Publication Number Publication Date
CA2441007A1 true CA2441007A1 (en) 2002-09-26
CA2441007C CA2441007C (en) 2009-06-09

Family

ID=23054783

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002441007A Expired - Lifetime CA2441007C (en) 2001-03-15 2002-03-15 Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids

Country Status (11)

Country Link
US (1) US8263582B2 (en)
EP (1) EP1392321B1 (en)
JP (3) JP2005508836A (en)
AT (1) ATE477804T1 (en)
AU (1) AU2002254205B2 (en)
CA (1) CA2441007C (en)
DE (1) DE60237363D1 (en)
DK (1) DK1392321T3 (en)
IL (2) IL157921A0 (en)
NZ (1) NZ528607A (en)
WO (1) WO2002074316A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143328A1 (en) * 2001-08-13 2009-06-04 Mcdonald George Method of Treating Cancer by Administration of Topical Active Corticosteroids
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
AU2003291362B2 (en) * 2002-11-08 2009-01-15 Schering Corporation Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
WO2005053612A2 (en) * 2003-11-26 2005-06-16 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
KR100638041B1 (en) * 2003-12-24 2006-10-23 주식회사 삼양사 A nanoparticle composition of a water-soluble drug for oral administration and a preparation method thereof
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20080102114A1 (en) * 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
DK1830857T3 (en) * 2004-12-30 2011-02-07 Soligenix Inc Beclomethasone Dipropionate and Prednisone to Reduce Mortality Associated with Graft-Versus-Host Disease
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2655682A1 (en) 2006-08-03 2008-02-07 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
EP2066309B1 (en) 2007-04-04 2012-08-29 Sigmoid Pharma Limited An oral pharmaceutical composition
DK2214679T3 (en) 2007-11-13 2019-05-20 Meritage Pharma Inc CORTICOSTEROID COMPOSITIONS
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20100183749A1 (en) * 2008-12-08 2010-07-22 Brey Robert N Topically active steroids for use in radiation and chemotherapeutics injury
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
EP2416811B1 (en) * 2009-04-09 2015-09-09 Actamax Surgical Materials LLC Hydrogel tissue adhesive having reduced degradation time
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
IT1405012B1 (en) 2010-08-06 2013-12-16 Sofar Spa COMPOSITIONS OF BECLOMETASONE DIPROPIONIONATO IN GASTRORESISTANT MICROSPHERES WITH MODIFIED RELEASE AND PROCESS FOR THEIR OBJECTION
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
PT2543357T (en) * 2011-07-07 2018-04-30 Holy Stone Healthcare Co Ltd Composition for use in treating and preventing inflammation related disorder
US10154964B2 (en) * 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US20160184474A1 (en) 2013-07-29 2016-06-30 Actamax Surgical Materials, Llc Low swell tissue adhesive and sealant formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (en) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral corticosteroid preparation
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (en) * 1989-11-22 1989-11-22 Draco Ab ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
JPH0840941A (en) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd Remedial preparation for inflammatory bowel disease
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
JPH1067657A (en) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd Multiple unit type long-acting pharmaceutical preparation
JPH10231242A (en) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk Long-acting diclofenac sodium composition
EP1017370B1 (en) * 1997-09-11 2003-10-29 Nycomed Danmark ApS MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
IT1301947B1 (en) * 1998-07-28 2000-07-20 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS OF BECLOMETASONE DEPROPIONED FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES OF THE MUCOSA
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2002058729A2 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies

Also Published As

Publication number Publication date
EP1392321B1 (en) 2010-08-18
AU2002254205B2 (en) 2007-05-10
US8263582B2 (en) 2012-09-11
EP1392321A1 (en) 2004-03-03
EP1392321A4 (en) 2007-10-24
CA2441007C (en) 2009-06-09
JP2005508836A (en) 2005-04-07
US20030055028A1 (en) 2003-03-20
DE60237363D1 (en) 2010-09-30
IL157921A0 (en) 2004-03-28
DK1392321T3 (en) 2010-11-29
WO2002074316A1 (en) 2002-09-26
JP2010106038A (en) 2010-05-13
JP2013216700A (en) 2013-10-24
JP5617015B2 (en) 2014-10-29
IL157921A (en) 2011-07-31
NZ528607A (en) 2007-11-30
ATE477804T1 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
CA2441007A1 (en) Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
AU6948994A (en) Iron-binding polymers for oral administration
CA2496864A1 (en) A pharmaceutical composition
WO2002045703A3 (en) Mixtures or organic compounds for the treatmentof airway diseases
WO1997015269A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
WO2003028633A3 (en) Parenteral delivery systems
YU58103A (en) Pharmaceutical dosage forms of epothilones for oral administration
WO2006017726A3 (en) Polysulfated glycosides and salts thereof
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
CA2362499A1 (en) Combinations of formoterol and mometasone furoate for asthma
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
WO2002047667A3 (en) Novel medicament compositions based on anticholinesterase drugs and on a steroid
CA2472954A1 (en) Aza-arylpiperazines
WO2005102358A3 (en) Silicone-substituted cox-2 selective inhibitors
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2004082590A3 (en) A low dose corticosteroid composition
WO2002087596A3 (en) Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
WO2003005967A3 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
WO2005023792A3 (en) Macrocyclic compounds useful as pharmaceuticals
JP2001510826A5 (en)
JP2003508467A5 (en)
AU2003290015A1 (en) Mastitis treatment
WO2000054780A3 (en) Corticosteroid formulation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220315